As the process determines the product, product characteristics of biological drugs need to be analysed thoroughly right from the beginning of the drug development process. Early understanding of structure-function relationships, aggregation, microheterogenicity, and glycosylation, and more, helps minimise development risks.
Enthera Pharmaceuticals Srl raises €28m in Series A financing
Latest NewsItalian start-up Enthera Pharmaceuticals has raised €28m to advance restorative therapy for type 1 diabetes and inflammatory bowel disease.
Vital expertise in oncolytic virus production
Latest NewsOncolytic viruses, viral vectors for gene therapy and viral-vectored prophylactic vaccines, are new, innovative, and already successful approaches for the treatment of severe diseases. The production of these viruses requires extensive experience and specially-designed GMP clean rooms. Vibalogics offers both.
Protection in case of SPCs for pharmaceuticals?
OpinionSPCs offer up to five and a half years of additional protection after patent expiration for pharmaceuticals in order to compensate the patent holder’s inability to exploit their inventions while products undergo lengthy regulatory approvals.
Polyphor AG bags CHF19.3 in equity financing
Latest NewsSwiss Polyphor AG has strengthened its financial flexibility with an equity-linked financing.
Interview: How to improve data analytics
BackgroundInterview with Ian Harrow from the Pistoia Alliance, about how to improve life sciences data management with help of a new digital toolkit that makes data Findable, Accessible, Interoperable, and Reusable – in brief: FAIR.
Rentschler Biopharma expands U.S. footprint
OpinionPrior to Danish Genmab A/S’s recent licence option deal with AbbVie Inc, Rentschler Biopharma has extended its collaboration with Genmab. European Biotechnology spoke with Rentschler Biopharma SE’s SVP Global BD Federico Pollano about the CDMO’s expertise in DuoBody® molecules production and the expansion of the CDMO’s U.S. production site in Milford.
A plucked chicken named Horizon Europe
Latest NewsAccording to current information, the European Research Framework Programme "Horizon Europe" is likely to be among the indirect victims of the Corona pandemic: A large part of the funds earmarked will now go to the € 750 billion rescue fund.
Defining the bioprocess is early quality control
Latest NewsAs the process determines the product, product characteristics of biological drugs need to be analysed thoroughly right from the beginning of the drug development process. Early understanding of structure-function relationships, aggregation, microheterogenicity, and glycosylation, and more, helps minimise development risks.
Quantro: Seed capital by Evotec and Boehringer
Latest NewsGermany’s Evotec SE and Boehringer Ingelheim Venture Fund have acquired equal minority stakes in Quantro Therapeutics GmbH, a recently established research-based biotech company based in Vienna. Evotec also entered into a comprehensive partnership with the Austrian start-up, that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programmes in cancer and other diseases. The Germans will provide hit identification services for Quantro’s proprietary anti-tumour projects.
Sourcing reference products
Latest NewsA biosimilar is a copy version of an approved, original biological medice whose patent protection has expired. The development strategies for biosimilar product and a new biological entity (NBE) differ in many ways.